2min chapter

Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Constellation Sales Process

There's a lot of interest in the space from larger pharmaceutical companies because there's unmet need. I mean, people really recognize that Jackified is great. But if it only works for 40% of patients to help their symptoms score and help their spleen volume, that's 60% of patients out there that aren't having disease control. It's kind of like, when I think of a drug, I'm like, Oh, yeah, it works for 85% of patients. Like it's crazy that there's a first line that's only 40%.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode